EMT-6-hPD-L1
Strain Information
Validation Data
Figure 1. Expression of human PD-L1 on EMT6-hPD-L1 cells was confirmed by flow cytometry.
EMT6-hPD-L1 cells and wild type EMT6 cells were stained with species-specific anti-PD-L1 antibodies. FACS analysis shows that human PD-L1 but not mouse PD-L1 was exclusively detectable on EMT6-hPD-L1 cells.
Figure 2. In vivo tumor growth curves in humanized EMT6-hPD-L1 syngeneic model.
BALB/c mice were subcutaneously injected 5×105 EMT6-hPD-L1 cells compared with wild type EMT6 cells as control. Tumor growth was monitored by measuring tumor size from day 7 after subcutaneous implantation.
Data shows that there were no significant differences between EMT6-hPD-L1 cells and wild type EMT6 cells in either tumorigenicity or tumor growth.
Figure 3. FACS analysis of PD-L1 expression on tumor cells derived from humanized EMT6-hPD-L1 syngeneic model with species-specific anti-PD-L1 antibodies.
Data shows that neither human PD-L1 nor mouse PD-L1 was detectable in EMT6-hPD-L1 knock-in tumor. This EMT6-hPD-L1 cell line can only be used for in vitro validation not for in vivo experiments.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
